Physician profile
Katherine E Mcclure
NPI 1932698727
$6,600.87
in general payments reported to CMS, 2019-2025
37 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $525 · 2021: $727 · 2022: $918 · 2023: $1,007 · 2024: $1,046 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,044 · Education: $95.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,043.65 |
| Education | $95.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $903.79 | 2020-2025 | Rinvoq, Skyrizi |
| Sun Pharmaceutical Industries INC. | $771.46 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $729.39 | 2019-2025 | Dupixent |
| Ucb, INC. | $568.14 | 2022-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $390.83 | 2019-2025 | |
| Lilly USA, LLC | $361.03 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $358.58 | 2019-2025 | |
| Janssen Biotech, INC. | $342.54 | 2022-2025 | Tremfya, Stelara, Simponi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $278.39 | 2019-2025 | Jublia, Duobrii, Siliq |
| Leo Pharma INC. | $268.50 | 2021-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $206.46 | 2025 | Nemluvio, Aklief |
| Amgen INC. | $176.08 | 2022-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $174.65 | 2025 | |
| Janssen Scientific Affairs, LLC | $122.03 | 2021 | |
| Vyne Pharmaceuticals INC. | $115.21 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $81.85 | 2023-2025 | Zoryve |
| Pfizer INC. | $80.45 | 2023-2025 | |
| Incyte Corporation | $68.61 | 2021-2024 | Opzelura |
| Smith+Nephew, INC. | $56.07 | 2022-2024 | Grafix Pl |
| Organon LLC | $52.26 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $46.66 | 2024-2025 | Sotyktu |
| Kyowa Kirin, INC. | $41.83 | 2023 | Poteligeo |
| Journey Medical Corporation | $41.23 | 2023-2025 | |
| Botanix Sb INC | $37.91 | 2025 | Sofdra |
| Almirall LLC | $37.62 | 2024-2025 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.66 | 2025 | Spevigo |
| Fidia Pharma USA INC. | $34.14 | 2024-2025 | |
| Dermavant Sciences, INC. | $33.15 | 2023 | Vtama |
| Merck Sharp & Dohme LLC | $26.52 | 2023 | Keytruda |
| Biofrontera INC. | $24.11 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $23.55 | 2022 | |
| Mylan Institutional INC. | $22.89 | 2023 | Hulio |
| Lnhc, INC | $22.43 | 2025 | Zelsuvmi |
| Organogenesis INC. | $21.07 | 2025 | Puraply Wound Matrix |
| Revance Therapeutics, INC. | $17.72 | 2025 | Daxxify |
| Helsinn Therapeutics (U.S.), INC. | $15.28 | 2021 | |
| Biotissue Holdings INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.